



In an ongoing effort to provide appropriate, affordable, healthcare options to our members, Willamette Valley Community Health CCO will be making several changes to the current formulary.

All formulary changes, additions and removals are thoroughly investigated, reviewed and approved by the Pharmacy & Therapeutics Committee. This Committee is comprised of several providers representing multiple specialties and clinics from our community. These recommendations were based on utilization, pharmacokinetic information and cost data.

We value your partnership as we continue to work toward our mutual goal of delivering the highest quality healthcare while ensuring affordability and accessibility. If you are interested in participating in the P & T Committee please contact the WVP Clinical Pharmacists at 503-371-7701 for more information.

WVCH Formulary Additions Effective 6/9/2018				
Name	Strength	Dosage Form	Route	Change
Entacapone	200 mg	Tablet	Po	Adding to formulary with PA criteria
Bydureon BCise autoinjector	2 mg/0.85 ml	Solution	SQ	Adding to formulary with PA criteria

WVCH Formulary Removals Effective 7/1/2018			
Name	Strength	Dosage Form	Route
Synarel (Nafarelin)	2 mg/ml	Solution	Nasal

WVCH Formulary Changes Effective 7/1/2018				
Name	Strength	Dosage Form	Route	Change
Carbidopa-Levodopa-Entacapone	18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 37.5-150-200 mg, 50-200-200 mg	Tablets	Po	Adding PA restrictions to medications
Ropinirole	0.25 mg, 0.5 mg, 1 mg, 2 mg	Tablet	Po	Removing PA restriction and adding QL of 60 tablets per month
Selegiline	5 mg	Tablet and capsule	Po	Adding PA restriction

Questions? Please contact WVCH at 503-584-2150 posted 6/4/2018